Study Summary
A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Want to learn more about this trial?
Request More InfoInterventions
CD19/BCMA Targeted CAR T-cells and dasatinibDRUG
Each subject receive CS1 Targeted CAR T-cells by intravenous infusion, and the dasatinib was combined according to the presumed regimens.
CD19/BCMA Targeted CAR T-cellsDRUG
Each subject receive CS1 Targeted CAR T-cells by intravenous infusion.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The First Hospital of Zhejiang Medical Colleage Zhejiang University | Hangzhou | Zhejiang | China |